• The popularity of GLP-1 medications has pushed pharmaceutical agents into the mainstream conversation on health and wellness. As consumer awareness grows, GLP-1 has surpassed its pharmaceutical roots and is now more perceived as a symbol of metabolic health.
Source: ChemBizR
    The popularity of GLP-1 medications has pushed pharmaceutical agents into the mainstream conversation on health and wellness. As consumer awareness grows, GLP-1 has surpassed its pharmaceutical roots and is now more perceived as a symbol of metabolic health. Source: ChemBizR
Close×

The popularity of GLP-1 medications such as Ozempic, Wegovy, and Mounjaro has pushed these pharmaceutical agents into the mainstream conversation on health and wellness. Initially developed for glycemic control in type 2 diabetes, these drugs are now popularly known for their weight loss benefits and appetite-suppressing effects. As consumer awareness grows, GLP-1 has surpassed its pharmaceutical roots and is now more perceived as a symbol of metabolic health. ChemBizR marketing and communication lead, Shivani Srivastava, offers insight.

This shift has prompted a new wave of innovation in the functional food and nutraceutical sectors, where companies are reimagining ingredient strategies that emulate or support GLP-1 pathways through dietary and supplement-based interventions. Rather than seeing GLP-1 as a drug-specific phenomenon, the market is now taking it as a metabolic framework: a blueprint around which future product development can be structured.

What is GLP-1 and why it matters

GLP-1, or glucagon-like peptide-1, is a hormone secreted by intestinal L-cells in response to food intake. It promotes glucose-dependent insulin secretion. Also, it delays gastric emptying, and influences satiety through neural pathways that act on the brain's appetite centres. These properties make it a critical hormone in the management of metabolic disorders, especially obesity and diabetes.

From a product development perspective, GLP-1 makes a highly desirable target because it modulates multiple physiological endpoints relevant to consumer health: blood glucose stability, appetite control, and body weight regulation. But the widespread reliance on synthetic GLP-1 receptor agonists brings with it cost burdens, medical access limitations, and potential side effects.

These shortcomings have opened the doors for ingredient innovation. The target is to stimulate endogenous GLP-1 secretion through dietary means that engage gut receptors, microbiota, and enteroendocrine signaling pathways.

Ingredient approaches

To make the complex science of GLP-1 more approachable, it helps to focus on how a handful of key ingredient categories interact with the gut-brain axis. Fermentable fibers like inulin and resistant starch can increase the production of short-chain fatty acids (SCFAs) in the colon, molecules that trigger GLP-1 secretion from intestinal cells. These same SCFAs are now being seen as supplements themselves, in the form of postbiotic capsules or powders.

Bitter compounds found in botanicals such as hops and gentian root stimulate receptors in the gut lining, indirectly encouraging GLP-1 release. This explains the rise of “functional bitters” marketed for appetite support. On the protein side, hydrolysed whey or soy peptides have demonstrated the ability to activate nutrient-sensing pathways that are connected to GLP-1 release.

Polyphenol-rich extracts, such as those from green tea and turmeric, add another layer. It influences inflammation, gut permeability, and microbial composition, all of which play assisting roles in GLP-1 modulation. The common thread in all these ingredients is their ability to communicate with the gut’s endocrine system, sometimes directly, sometimes through microbial intermediaries, to shift appetite, insulin sensitivity, or satiety.

Ingredient mechanism table

Source: ChemBizR
Source: ChemBizR

Market signals: how companies are building around GLP-1

As GLP-1 traverses from a medical therapy to a consumer wellness narrative, companies are responding with positioning strategies that align with regulatory boundaries. At the same time, they are capitalizing on emerging consumer interest. Direct GLP-1 claims are not permissible under current FDA or EFSA guidelines.

This is nudging brands to use alternative language such as "supports satiety," "promotes appetite balance," or "helps manage weight through gut-brain signalling." The language often hinges on the concept of hormone modulation or gut-derived metabolic control, with an emphasis on natural pathways.

In 2024, Nestlé set forth its Vital Pursuit line of frozen meals made specifically for individuals using GLP-1 receptor agonists. These meals present portion control and macronutrient balance tailored to users experiencing reduced appetite and altered nutrient absorption.

Conagra's Healthy Choice meals began carrying a "GLP-1 Friendly" label, denoting high protein and fiber content designed to complement pharmaceutical interventions. These mainstream food companies are quite effectively narrowing the space between medical nutrition and everyday convenience.

Also, in October 2024, in the functional food and supplement area, Supergut set in motion its GLP-1 supportive bars and shakes that contain high levels of resistant starch and inulin. Their positioning puts focus on natural stimulation of appetite hormones through microbiome fermentation.

In September 2024, Lemme launched its GLP-1 Daily supplement, and in December 2024, Le-Vel introduced its MyGLP system using blends of plant extracts including saffron, lemon polyphenols, and blood orange to promote fullness and support metabolic health. While the scientific validation for many of these blends remains early-stage, their formulation logic is getting more aligned with known GLP-1 pathways.

At the ingredient and B2B innovation level, in October 2024, ADM revealed its GLP-1 supportive ingredient solutions and resistant starches made to enhance endogenous GLP-1 secretion. These ingredients are being marketed to food and beverage formulators with a target to serve populations that are cutting off GLP-1 drugs or seeking non-pharmaceutical options. ADM's messaging emphasizes support for satiety, metabolic balance, and blood sugar control through fermentation-mediated mechanisms.

Various new product launches have enhanced this trend further in 2025. Elénzia announced Control, a supplement shown to boost GLP-1 levels naturally using lemon flavonoids as well as milk thistle. Nexira launched Carolean™ and VinOgrape™, ingredients designed to stimulate GLP-1 through gut fermentation and fiber pathways. Gencor brought in Trpti™, an oleoylethanolamide (OEA)-based ingredient that acts on GLP-1 receptors through GPR119.

Retailers like The Vitamin Shoppe set in motion a GLP-1 Support line, while Youtheory piloted a trio of products addressing nutrient depletion and muscle loss for those on GLP-1 medications. These developments of 2025 point to the recognition of GLP-1 as a product design vertical across food, supplement, and wellness platforms.

Brand launches (market signals)

Source: ChemBizR
Source: ChemBizR

Science vs. regulation: navigating a claim-restricted zone

The regulatory framework for GLP-1-related claims stays complex. While preclinical and early clinical studies support the GLP-1-modulating potential of several ingredients, the majority of evidence is still derived from surrogate endpoints or mechanistic models. Regulatory authorities have been clear that direct references to GLP-1 are not permissible in consumer-facing claims, especially given the association with prescription medications.

Brands must rely on structure-function claims that refer to appetite control, satiety, or metabolic wellness. But the potential for market leadership stays in conducting well-designed human trials that include GLP-1 or related biomarkers as secondary endpoints. This method could create a defensible position in what is currently a crowded but under-substantiated space.

Designing for GLP-1: a strategic frontier

GLP-1 is no longer limited to endocrinology textbooks or prescription formularies. It is becoming a foundational concept in functional nutrition. Also, it is reshaping how ingredients are evaluated and how formulations are made. The future is in multi-pathway strategies that combine fermentable fibers, protein hydrolysates, polyphenols, and postbiotics in targeted formats.

There is also notable whitespace in formulating for demographic groups that are underserved by current GLP-1 therapies, such as older adults, men with visceral fat, and individuals with prediabetes. A "pharma-grade" approach to ingredient sourcing, dose standardization, and clinical substantiation will likely define the next generation of metabolic health products.

Companies that begin integrating GLP-1 thinking now, at the formulation, regulatory, and positioning levels, will be best positioned to lead as the convergence of pharma and functional continues to accelerate.

Packaging News

Melbourne-based packaging innovator Onpack has joined forces with fast-rising hydration brand Rippl to deliver a sustainable, fast-turnaround packaging solution that merges high-quality digital printing with fully recyclable aluminium cans.

Big Bag Recovery has partnered with GT Recycling as its new processing partner to strengthen local recycling and circular economy outcomes in Victoria.

Close the Loop has appointed long-time team member Kesh Nair as its new CEO for Australia, in a move that signals the company’s sharpened strategic focus and leadership reset.